Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2618 + Penpulimab + Chemotherapy in R/M HNSCC
NCT05783921Phase 2Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- May 2023
- Primary completion
- Aug 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of TQB2618 in head and neck squamous cell carcinoma (HNSCC), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Progression-Free Survival up to 2 years and Objective Response Rate up to 2 years. Status: unknown.
02
Drugs
TQB2618
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05783921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05783921.